Zynerba Pharmaceuticals (ZYNE) Stock Forecast, Price Target & Predictions
ZYNE Stock Forecast
Zynerba Pharmaceuticals stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
ZYNE Analyst Ratings
Buy
According to 1 Wall Street analysts, Zynerba Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ZYNE stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 23, 2022 | Canaccord Genuity | Buy | Buy | Hold |
Row per page
Go to10
Zynerba Pharmaceuticals's last stock rating was published by Canaccord Genuity on Jun 23, 2022. The company gave ZYNE a "Buy" rating, the same as its previous rate.
Zynerba Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FLGC | Flora Growth | $1.13 | $173.50 | 15253.98% | Hold |
| ZYNE | Zynerba Pharmaceuticals | $1.30 | $11.00 | 746.15% | Buy |
| EBS | Emergent BioSolutions | $9.97 | $51.50 | 416.55% | Buy |
| COLL | Collegium Pharmaceutical | $30.18 | $40.50 | 34.19% | Buy |
| ITCI | Intra-Cellular Therapies | $88.22 | $94.50 | 7.12% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| CLVR | Clever Leaves | - | $4.30 | - | Buy |
| PAHC | Phibro Animal Health | $25.27 | $18.67 | -26.12% | Buy |